The Fellow on Call: The Heme/Onc Podcast

In this podcast, Vineetha Thomas, a clinical pharmacist specializing in genitourinary oncology, discusses the selection of drugs for prostate cancer, their side effects, and the role of chemotherapy. They also explore specific medications like prednisone, sipuleucel-T, radium 223, and lutetium-177. Additionally, they examine the importance of monitoring bone health in prostate cancer patients and the role of clinical pharmacists in prostate cancer treatment.

Prostate cancer is one of the common cancers diagnosed each year in males. In this new series, we will go through the ins-and-outs of this disease. As medical oncologists, there is so much more to prostate cancer than we see. In our future episodes, we will also highlight the important role of pharmacists, radiation oncologists, and urologists in disease management! Content: - What is the incidence of prostate cancer? - What are the screening guideline recommendations?- How do we diagnose prostate cancer?- How do we risk stratify patients with prostate cancer?- What additional imaging, if any, is needed as part of our workup of prostate cancer? - What is the overview regarding treatment of prostate cancer?- What is the overview about what to expect after surgery or radiation for prostate cancer? - What are key terms we need to know in prostate cancer? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Pharmacist Renee McAllister discusses managing extravasation accidents, pharmacy operations, ideal body weight vs. AUC, giving G-CSF, and supportive care tips in hematology and oncology. They also emphasize the importance of staffing and safety checks in administering inpatient chemo, relying on primary sources for drug information, and the role of pharmacists in chemotherapy management.

The podcast discusses the basics of pharmacology in oncology, including the differences between irritants and vesicants, the need for central access in patients receiving therapy, and an overview of chemotherapy side effects.

The hosts discuss the importance of understanding chemotherapy fundamentals, counseling patients, and administering drugs. They explore treatment regimens, valuable resources, and the three main categories of chemotherapy: cytotoxic, immune, and targeted therapy. The chapter also covers important aspects of chemotherapy and previews upcoming topics.

Explore warfarin and enoxaparin failure in the context of anticoagulation. Discuss alternative options for patients with anti-phospholipid antibody syndrome (APLS) whose warfarin treatment failed. Learn about distinguishing new and residual clots on imaging and the implications. Understand APLS, its impact on lab testing, and accurate diagnosis. Explore the correlation between INR values and factor 10 activity in patients with lupus anticoagulants.

This podcast discusses the workup for anticoagulation failure, focusing on DOAC failure. They explore challenges and considerations, including verifying blood thinner levels, assessing patient adherence, and exploring anatomic reasons for clot formation. They also discuss alternative anticoagulants like warfarin.

This podcast dives deep into the management of relapsed diffuse large B-cell lymphoma, exploring innovative treatments like selective antibodies against CD19. The discussions highlight exciting alternative therapies, including loncastuximab and combination regimens with tafacitimab and lenalidomide. Listeners hear about the promising results from clinical trials and the evolving strategies post-CAR-T therapy. It also evaluates the potential of allogeneic transplants in DLBCL management, painting a hopeful future for lymphoma treatments.

The discussion centers on managing relapsed diffuse large B-cell lymphoma (DLBCL) and dives into complex treatment strategies. The hosts share insights on dealing with CNS involvement, comparing CAR-T therapy with autologous transplant options. Tailoring treatment for individual patients is emphasized, especially in elderly cases where traditional therapies might not be viable. The episode underscores the significance of innovative approaches like polituzumab-vidotin to improve outcomes, providing a rich blend of expertise and relatable anecdotes.

Explore the challenging landscape of primary refractory diffuse large B-cell lymphoma (DLBCL) management. Learn about the critical distinctions between primary refractory and relapsed disease. CAR-T therapy takes center stage, showcasing its role and the need for effective bridging strategies. A detailed case study of a patient reveals the complexities of treatment regimens. Finally, discover the importance of careful post-infusion monitoring and the advancements in managing refractory cases.